Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AstraZeneca Integrates R&D in Japan into AZ Global Development
January 19, 2004
- WEBSITE NEWS
January 19, 2004
- Semi-annual Business Results
January 12, 2004
- Korosho Starts General Review of Post-Marketing Safety Policies
January 12, 2004
- Funding for Disease Measures Up Slightly in Korosho's FY2004 Budget
January 12, 2004
- Safety and Efficacy of Pravastatin in GVHD Proven: J-HOCS Study
January 12, 2004
- Korosho Earmarks Budget to Standardize Drug Bar Coding
January 12, 2004
- Ain Pharmaciez: Strong Growth in Semiannual Sales, Profits
January 12, 2004
- METI Receives Initial Budget Allocation of \857.6 Bil.
January 12, 2004
- Nippon Kayaku Expects Major New Products after 2008: Mr Shimada
January 12, 2004
- Korosho Raises Attention to Toxic Epidermal Necrolysis due to Ticlopidine: Safety Info
January 12, 2004
- FPMAJ Is Eager to Take Measures to Prevent Medical Accidents
January 12, 2004
- Obesity in Men, Low Weight in Girls Increasing: Korosho Survey
January 12, 2004
- Banyu Aims to Boost Nu-Lotan's Market Share to 30%
January 12, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 12, 2004
- IMS Japan Aims to Become a Services-based Company: President Saeki
January 12, 2004
- ON THE MOVE
January 12, 2004
- Time to New Drug Approval Down Sharply Since Mid-90s: OPIR
January 12, 2004
- Test Kit to Be Developed to Predict Effects of Morphine
January 12, 2004
- BUSINESS NEWS IN BRIEF
January 12, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…